CELL AND GENE THERAPY INSIGHTS

June 2019 Issue

Volume 5 Issue 6

Cell and Gene Therapy Insights Volume 5 Issue 6
Download PDF

Featuring

Issue Spotlight: Global Regulatory Update
Other articles
Webinars

SPOTLIGHT

Global Regulatory Update
Christiane Niederlaender
Guest Editor:
Christiane Niederlaender, Vice President Technical

Editorial

European developments in ATMP Regulation

European developments in ATMP Regulation

Christiane Niederlaender
24 June 2019
Read

Perspective

EU market authorisation strategy: lessons from the first 22 ATMP submitted to the EMA

EU market authorisation strategy: lessons from the first 22 ATMP submitted to the EMA

Oliver Ball, Sarah Robinson, Christopher Bravery
25 June 2019
Read
Facilities for the future: design & qualification of aseptic manufacturing facilities for cell and gene therapy

Facilities for the future: design & qualification of aseptic manufacturing facilities for cell and gene therapy

Neil WA McGowan, John DM Campbell
25 June 2019
Read
Gene therapy success: how to keep its promises and improve – a regulatory perspective

Gene therapy success: how to keep its promises and improve – a regulatory perspective

Filomena Nappi, Francesca Capone, Maria Cristina Galli
24 June 2019
Read
The impact of regulatory strategy on business goals: uniQure’s Phase 3 product optimization for hemophilia B

The impact of regulatory strategy on business goals: uniQure’s Phase 3 product optimization for hemophilia B

A Kuta, E Sawyer, M Cantor et al.
24 June 2019
Read

Interview

Korea’s evolving regulatory landscape for cell & gene therapies

Korea’s evolving regulatory landscape for cell & gene therapies

Jaeseung Lim
24 June 2019
Read
US FDA goals and priorities for cell & gene therapy regulation

US FDA goals and priorities for cell & gene therapy regulation

Peter Marks
24 June 2019
Read
Update on the regulatory environment for ATMPs in Israel

Update on the regulatory environment for ATMPs in Israel

Ofra Axelrod
24 June 2019
Read

Regulatory Insight

Experiences from Japan: conditional and time-limited approval – an early approval scheme for regenerative medical products

Experiences from Japan: conditional and time-limited approval – an early approval scheme for regenerative medical products

Y Maruyama, M Kasai, Y Fujiwara et al.
24 June 2019
Read

Journal articles

Expert Roundtable Video

AAV vector process development: achieving high purity & high yield – experiences from the frontline

AAV vector process development: achieving high purity & high yield – experiences from the frontline

M Bakhshayeshi, M Mercaldi, M Hebben et al.
7 June 2019
Watch

Expert Roundtable

AAV vector process development: achieving high purity and high yield – experiences from the frontline

AAV vector process development: achieving high purity and high yield – experiences from the frontline

M Bakhshayeshi, M Mercaldi, M Hebben et al.
7 June 2019
Read

Webinars